Madison-based Stratatech Corp. is getting a $4.6 million grant to help fund the start of clinical trials of ExpressGraft, a skin substitute designed to heal diabetes-related foot ulcers. Founded in 2000 based on discoveries at UW-Madison, Stratatech makes tissue products described on the company’s website as “nearly identical” to human skin. The company has 32 employees and will likely add more staff in 2012, Allen-Hoffmann said, but she could not yet estimate how many.
Office of Strategic Communication